ConductScience.org, home

Paper34975752

Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.

Das L and 13 others. Front Endocrinol (Lausanne), 2021. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. Papers, record 34975752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34975752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
PubMed
Journal
Front Endocrinol (Lausanne)
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.65
iCite
Revised in PubMed
2022-02-15
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Das LLiza
2Gupta NNidhi
3Dutta PPinaki
4Walia RRama
5Vaiphei KKim
6Rai AAshutosh
7Radotra BDBishan Dass
8Gupta KKirti
9Sreedharanunni SSreejesh
10Ahuja CKChirag Kamal
11Bhansali AAnil
12Tripathi MManjul
13Sood RRidhi
14Dhandapani SSivashanmugam

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenomaMajor topic
Early Medical InterventionMajor topic
Pituitary NeoplasmsMajor topic
TemozolomideMajor topic
Adult
Cohort Studies
Female
Humans
India
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Invasiveness
Prognosis
Retrospective Studies
Treatment Outcome

Source PubMed

Download CSV of topics

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130031177Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.World Neurosurg2018https://conductscience.org/library/papers/30031177PubMed
230210447Imatinib Inhibits GH Secretion From Somatotropinomas.Front Endocrinol (Lausanne)2018https://conductscience.org/library/papers/30210447PubMed
326614517Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.J Neurooncol2016https://conductscience.org/library/papers/26614517PubMed
433285600Bevacizumab in Aggressive Pituitary Adenomas - Experience with 3 Patients.Exp Clin Endocrinol Diabetes2021https://conductscience.org/library/papers/33285600PubMed
531311005How and when to use temozolomide to treat aggressive pituitary tumours.Endocr Relat Cancer2019https://conductscience.org/library/papers/31311005PubMed
631746334Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.J Clin Endocrinol Metab2020https://conductscience.org/library/papers/31746334PubMed
731349217Treatment and long-term outcomes in pituitary carcinoma: a cohort study.Eur J Endocrinol2019https://conductscience.org/library/papers/31349217PubMed
831808044Definition and diagnosis of aggressive pituitary tumors.Rev Endocr Metab Disord2020https://conductscience.org/library/papers/31808044PubMed
920660056Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.J Clin Endocrinol Metab2010https://conductscience.org/library/papers/20660056PubMed
1033089448Differential independent impact of the intraoperative use of navigation and angled endoscopes on the surgical outcome of endonasal endoscopy for pituitary tumors: a prospective study.Neurosurg Rev2021https://conductscience.org/library/papers/33089448PubMed
1134295309Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.Front Endocrinol (Lausanne)2021https://conductscience.org/library/papers/34295309PubMed
1230610566The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.Endocr Pathol2019https://conductscience.org/library/papers/30610566PubMed
1332415572Ki67 in endocrine neoplasms: to count or not to count, this is the question! A systematic review from the English language literature.J Endocrinol Invest2020https://conductscience.org/library/papers/32415572PubMed
1425027022The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy.J Exp Clin Cancer Res2014https://conductscience.org/library/papers/25027022PubMed
1528432119Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.Eur J Endocrinol2017https://conductscience.org/library/papers/28432119PubMed
1630306782Aggressive and malignant pituitary tumours: state-of-the-artEndocr Relat Cancer2018https://conductscience.org/library/papers/30306782PubMed
1729381964Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.Medicine (Baltimore)2017https://conductscience.org/library/papers/29381964PubMed
1823400299A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.Acta Neuropathol2013https://conductscience.org/library/papers/23400299PubMed
1931267325Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.Endocrine2019https://conductscience.org/library/papers/31267325PubMed
2016750503Temozolomide: a novel treatment for pituitary carcinoma.Lancet Oncol2006https://conductscience.org/library/papers/16750503PubMed

See all 33 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42573676Determinant factors for headache at acromegaly diagnosis: findings from an Iberian multicenter study encompassing 726 patients.J Endocrinol Invest2026https://conductscience.org/library/papers/42573676PubMed
42557589Can acromegaly be controlled in all cases?J Neuroendocrinol2026https://conductscience.org/library/papers/42557589PubMed
41894067Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study.Pituitary2026https://conductscience.org/library/papers/41894067PubMed
40806825Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas.J Clin Med2025https://conductscience.org/library/papers/40806825PubMed
39736867Everolimus in pituitary tumor: a review of preclinical and clinical evidence.Front Endocrinol (Lausanne)2024https://conductscience.org/library/papers/39736867PubMed
39224564Diagnosis and Management of Aggressive/Refractory Growth Hormone-Secreting Pituitary Neuroendocrine Tumors.Int J Endocrinol2024https://conductscience.org/library/papers/39224564PubMed
38760632Medical treatment of functional pituitary adenomas, trials and tribulations.J Neurooncol2024https://conductscience.org/library/papers/38760632PubMed
38738958The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment.CNS Neurosci Ther2024https://conductscience.org/library/papers/38738958PubMed
38370355Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.Front Endocrinol (Lausanne)2024https://conductscience.org/library/papers/38370355PubMed
38202123Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.J Clin Med2023https://conductscience.org/library/papers/38202123PubMed
37871278Epigenome-wide association study of systemic effects of obesity susceptibility in human twins.Epigenetics2023https://conductscience.org/library/papers/37871278PubMed
37720528Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37720528PubMed
35059545Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.J Endocr Soc2022https://conductscience.org/library/papers/35059545PubMed

Download CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34975752

GET https://conductscience.org/api/papers/v1/34975752/references?page=2